To evaluate the efficacy of PBTZ169 in combination with a range of other anti-tuberculosis (TB) drugs, our collaborators from the Cole lab, at the Global Health Institute of the EPFL, used in vitroassays and mouse models in order to design a new regimen against active TB. Notably, synergism could be observed when PBTZ169 was applied in combination with bedaquiline, clofazimine, delamanid and sutezolid.
These observations strongly suggest that the addition of PBTZ169 to innovative and optimized regimens can be beneficial to treat TB. The results of this study are collected in an article published in the journal Antimicrobial Agents and Chemotherapy, and the full text is available here:
Lupien A, Vocat A, Foo CS, et al. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrob Agents Chemother. 2018;62(11):e00840-18. Published 2018 Oct 24. doi:10.1128/AAC.00840-18